-43.7%
SNAP vs GSK
+62.2%
-106.0%
-77.5%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 3y.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | -4.0% | -1.9% | -2.1% | -4.1% |
| 7D | +0.7% | -1.8% | +2.6% | +0.7% |
| 30D | +2.6% | -2.2% | +4.8% | +2.6% |
| 3M | -9.9% | -1.8% | -8.1% | -9.9% |
| 6M | +1.9% | -10.6% | +12.5% | +1.3% |
| YTD | -32.2% | +4.4% | -36.6% | -32.2% |
| 1Y | -22.8% | +30.4% | -53.3% | -22.5% |
| All | -43.7% | +62.2% | -106.0% | -43.4% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 3y: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
3y analysis · Full analysis span regression · 6 months rolling